How Do Retatrutide, Cagrilintide, and Eloralintide Compare on Weight-Loss and Appetite-Suppression Effect Sizes in 2026 Obesity Studies?

Across 2026-era obesity data, retatrutide (triple GLP-1R/GIPR/GCGR agonist) leads on absolute weight-loss magnitude at approximately 28% mean body-weight reduction at 80 weeks. Cagrilintide combined with semaglutide reaches approximately 22.7% at 68 weeks via a distinct amylin-plus-GLP-1 pathway. Eloralintide, a selective amylin receptor agonist, shows approximately 8 to 9% at 26 weeks as monotherapy.

What Receptor Pathways Do These Three Compounds Use to Suppress Appetite?

Retatrutide engages GLP-1R, GIPR, and GCGR simultaneously, driving hypothalamic satiety signalling, incretin-amplified insulin release, and GCGR-mediated thermogenesis. Cagrilintide is a long-acting amylin analogue acting at amylin receptors (AMY1 through AMY3) in the area postrema and nucleus tractus solitarius. Eloralintide is a selective CALCR/RAMP agonist targeting the same amylin-receptor complex with higher receptor selectivity and a distinct pharmacokinetic profile.

The GLP-1R axis in retatrutide suppresses appetite through arcuate nucleus POMC neuron activation and reduces gastric emptying rate. GIPR co-agonism adds a hypothalamic satiety signal independent of GLP-1R. The GCGR component drives hepatic fatty acid oxidation and brown adipose tissue thermogenesis, an energy-expenditure vector absent from incretin-only compounds.

Amylin receptors are heterodimers of the calcitonin receptor (CALCR) and receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). Cagrilintide activates all three AMY subtypes and also engages the calcitonin receptor directly. Eloralintide is engineered for higher AMY1/AMY3 selectivity over CALCR alone, which is the design rationale for its differentiated tolerability profile relative to pramlintide.

The mechanistic separation between the incretin-axis compounds and the amylin-axis compounds is protocol-critical. Retatrutide and cagrilintide/eloralintide operate through non-overlapping primary receptor systems. This non-overlap is the pharmacological basis for the CagriSema combination strategy and for any future amylin-plus-triple-agonist stack design.

What Are the Quantified Weight-Loss Effect Sizes Across Available Trial Data?

No head-to-head trial compares these three compounds directly. Retatrutide 12 mg produced approximately 28% at 80 weeks (TRIUMPH-1, 2025). CagriSema produced approximately 22.7% at 68 weeks (REDEFINE-1, 2025) and eloralintide produced approximately 8 to 9% at 26 weeks in Phase 2 monotherapy, all figures drawn from separate trials with different durations and populations.

The TRIUMPH-1 Phase 3 trial (Eli Lilly, December 2025) enrolled adults with obesity or overweight with at least one weight-related comorbidity. The 12 mg arm produced approximately 28% mean weight loss at 80 weeks. Approximately 45% of participants achieved at least 30% body weight reduction.

The 9 mg arm produced approximately 25% weight loss and the 4 mg arm approximately 24%, versus approximately 4% in the placebo arm. These dose-response figures establish the TRIUMPH-1 benchmark for the triple-agonist mechanism. No dual-agonist compound has produced a comparable effect size at equivalent trial duration.

REDEFINE-1 (Novo Nordisk, 2025) tested the CagriSema combination against semaglutide monotherapy and placebo, producing approximately 22.7% mean weight loss at 68 weeks versus approximately 15.7% for semaglutide monotherapy alone. The incremental benefit of the amylin-plus-GLP-1 combination over semaglutide monotherapy was approximately 7 percentage points.

Eloralintide Phase 2 data (Zealand Pharma and Boehringer Ingelheim) showed approximately 8 to 9% body weight reduction at 26 weeks in adults with obesity. This monotherapy figure establishes the amylin-selective baseline but is not directly comparable to the combination or triple-agonist data. No Phase 3 data for eloralintide monotherapy in obesity had been published as of early 2026.

How Do Appetite-Suppression Mechanisms Differ Across the Three Compounds?

Retatrutide suppresses appetite primarily through hypothalamic GLP-1R and GIPR signalling, reducing meal initiation and increasing satiety duration. Cagrilintide and eloralintide suppress appetite through the area postrema and NTS amylin-receptor complex, reducing meal size via a vagal-afferent pathway. These are anatomically and pharmacologically distinct satiety circuits.

The GLP-1R satiety signal operates through arcuate nucleus POMC neurons and downstream melanocortin-4 receptor (MC4R) activation. This pathway reduces meal frequency and total caloric intake. The GIPR hypothalamic signal is additive but mechanistically parallel, both converging on reduced appetite drive through central melanocortin circuitry.

The amylin-receptor satiety signal is routed through the area postrema (AP) and nucleus tractus solitarius (NTS), which are circumventricular organs outside the blood-brain barrier. Amylin receptor activation in the AP/NTS reduces meal size by accelerating the satiety signal during eating, rather than reducing meal initiation. This is a mechanistically distinct satiety modality from the hypothalamic GLP-1R/GIPR signal.

The distinction has direct protocol implications. Stacking an amylin-pathway compound with a GLP-1R agonist targets two non-overlapping satiety circuits simultaneously, which is the rationale behind CagriSema. Adding eloralintide to a GLP-1R agonist or to retatrutide would theoretically engage the same AP/NTS amylin circuit as cagrilintide, but with a different receptor-selectivity and pharmacokinetic profile. No co-administration data exist for eloralintide with any incretin compound as of early 2026.

How Do These Three Compounds Map Onto a Protocol Blueprint for Obesity Stacks?

The three compounds occupy distinct mechanistic tiers in a protocol blueprint: retatrutide as a triple-axis incretin anchor, cagrilintide as an amylin-pathway add-on with established combination data (CagriSema), and eloralintide as an amylin-selective candidate with no co-administration data. Stacking cagrilintide with retatrutide is mechanistically coherent but entirely without controlled evidence. Stacking eloralintide with any incretin compound is interaction-unknown.

Why Does the Amylin Pathway Matter for Protocol Designers Moving Beyond GLP-1 Monotherapy?

The amylin pathway (area postrema / NTS) operates independently of hypothalamic GLP-1R and GIPR signalling. CagriSema's approximately 7 percentage-point weight-loss increment over semaglutide monotherapy in REDEFINE-1 is the first Phase 3 quantification of what dual-circuit appetite suppression adds. Protocol designers can treat this increment as the empirical floor for amylin-pathway augmentation of a GLP-1R anchor.

The area postrema is a circumventricular organ with a fenestrated blood-brain barrier, making it directly accessible to circulating peptides. Amylin receptor activation here generates a satiety signal transmitted to the NTS and then to the hypothalamus via ascending vagal afferents. This circuit is anatomically upstream of the hypothalamic melanocortin system, meaning it can modulate meal-size independently of whether GLP-1R/GIPR hypothalamic signalling is already saturated.

The practical implication for protocol design is that amylin-pathway augmentation retains mechanistic utility even at maximum GLP-1R agonist doses. The CagriSema REDEFINE-1 data confirm this: the approximately 7 percentage-point increment was observed on top of semaglutide 2.4 mg, a dose at which GLP-1R satiety signalling is near-maximal. This is the empirical basis for the amylin-combination strategy.

Eloralintide's selective AMY1/AMY3 profile versus cagrilintide's broader AMY1 through AMY3/CALCR engagement represents a receptor-selectivity variable not yet tested in a combination trial. Whether higher amylin-receptor selectivity translates to a different weight-loss increment or tolerability profile in combination with incretin compounds remains an open protocol-design question as of early 2026.

How Do Tolerability Profiles Differ and What Does This Mean for Stack Sequencing?

Retatrutide's GI adverse-event profile is driven by GLP-1R-mediated gastric emptying slowing, with nausea peaking during dose escalation. Cagrilintide's amylin-pathway tolerability is characterised by injection-site reactions and modest nausea, distinct from GLP-1R-driven GI effects. Eloralintide's selective receptor profile was designed to reduce calcitonin-receptor-mediated nausea relative to pramlintide. These distinct tolerability signatures constrain stack-sequencing decisions.

In the REDEFINE-1 CagriSema trial, nausea was the most common adverse event, reported in approximately 30% of the combination arm versus approximately 21% for semaglutide monotherapy. The additive nausea signal in the combination arm is consistent with two mechanistically distinct GI-motility pathways being engaged simultaneously. Protocol designers should treat the combination nausea increment as a tolerability cost of dual-circuit appetite suppression.

Retatrutide's GCGR component adds a modest heart-rate increment of approximately 2 to 4 bpm at 12 mg (Phase 2 data). This cardiovascular signal is absent from amylin-pathway compounds. Any stack combining retatrutide with cagrilintide or eloralintide carries the GLP-1R/GCGR GI and cardiovascular tolerability profile of retatrutide plus the amylin-pathway nausea increment, a combined tolerability burden without controlled safety data.

What Are the Critical Evidence Gaps for Protocol Designers in Early 2026?

Three gaps are protocol-critical: no head-to-head trial compares these three compounds directly; no co-administration RCT tests retatrutide with any amylin-pathway compound; and eloralintide has no Phase 3 obesity data. Effect-size comparisons across separate trials are confounded by different durations, populations, and comparator designs. All cross-compound interaction classes in this blueprint are extrapolated from single-compound or two-compound data.

The absence of a direct head-to-head trial means that the approximately 28% figure for retatrutide and the approximately 22.7% figure for CagriSema cannot be compared as if measured in the same population. TRIUMPH-1 ran to 80 weeks while REDEFINE-1 ran to 68 weeks. Baseline BMI distributions, geographic populations, and placebo-arm weight loss differ across trials.

These confounders preclude rank-ordering by effect size alone. The retatrutide-plus-amylin-compound stack is the most mechanistically compelling unresolved question. Retatrutide covers the incretin and thermogenic axes while cagrilintide or eloralintide would add the AP/NTS amylin circuit. No safety, tolerability, or efficacy data exist for this combination as of early 2026.

Long-term cardiovascular outcomes data are absent for all three compounds in combination contexts. Retatrutide's GCGR-driven heart-rate signal, cagrilintide's calcitonin-receptor activity, and eloralintide's CALCR/RAMP selectivity each carry distinct cardiovascular interaction hypotheses.

None of these cardiovascular interaction hypotheses have been tested in co-administration trials. This is the binding constraint on any multi-compound obesity stack that includes both an incretin-axis anchor and an amylin-pathway compound. How Does Retatrutide's Triple Agonist Activity Change Protocol Design for Weight Loss Versus Dual Agonists in 2026? What Does the 2026 CagriSema Evidence Say About Combining Cagrilintide with Semaglutide for Obesity? What Do 2026 Primary Studies Show About GLP-1/GIP Dual Agonists Versus GLP-1 Monotherapy for Body-Weight Loss and Cardiometabolic Outcomes? What Are the Evidence-Based Dosing Protocols for Retatrutide in the TRIUMPH Phase 3 Trial Versus Tirzepatide in 2026? What Does 2026 Research Show About Semaglutide's Role in Metabolic Medicine?